Stemtech (NASDAQ: STEK) files 12b-25; Q1 2026 10-Q delayed
Rhea-AI Filing Summary
Stemtech Corporation submitted a Rule 12b-25 notice stating its Form 10-Q for the quarter ended March 31, 2026 could not be filed on time because the company needs additional time to complete the financial statements and prepare the Form 10-Q. The company states it expects to use no more than the additional five calendar days allowed to complete and file the report.
The notice also discloses that the company has not filed its Annual Report on Form 10-K for the fiscal year ended 2025. The 12b-25 was signed by CEO Charles S. Arnold on May 14, 2026.
Positive
- None.
Negative
- None.
Insights
Routine late-filing notice; procedural impact only.
The filing documents a Rule 12b-25 notification that the Form 10-Q for the quarter ended March 31, 2026 will be delayed by up to five calendar days while the company completes its financial statements. This is a procedural disclosure that preserves the issuer's ability to cure a late filing within the narrow statutory window.
Risks depend on why the financial statements remain incomplete; subsequent filings may disclose material changes. Watch for the filed Form 10-Q within the stated cure period and for the outstanding Form 10-K for fiscal 2025 in later periodic reports.
Key Figures
Key Terms
Rule 12b-25 regulatory
Form 10-Q regulatory
Form 10-K regulatory
FAQ
Why did Stemtech (STEK) file a Rule 12b-25 for its March 31, 2026 10-Q?
When does Stemtech expect to file the delayed Form 10-Q for Q1 2026?
Has Stemtech filed its annual 10-K for fiscal 2025?
Who signed the 12b-25 notice for Stemtech and when was it signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.